MARITIME-OSA involves two Phase 3 studies for people who are living with obstructive sleep apnea (OSA) and overweight or obesity, with or without positive airway pressure (PAP) therapy. In these studies, we are exploring if an investigational medicine (a monthly injection) can help reduce the severity of sleep apnea events.
MARITIME-OSA-1 is for participants who are using PAP therapy.
MARITIME-OSA-2 is for participants who are not using PAP therapy.
Amgen is currently recruiting for MARITIME-OSA-1 and MARITIME-OSA-2.
You, or someone you care for, may be able to take part if you/they:
Participants will receive either the investigational medicine or a placebo, which contains no actual medicine. A placebo looks the same as the investigational medicine.
The studies are made up of 3 parts.
Screening period
(up to 5 weeks)
PARTICIPANT RESPONSIBILITIES:
Study treatment period
PARTICIPANT RESPONSIBILITIES:
Follow-up period
(about 12 weeks / 3 months)
PARTICIPANT RESPONSIBILITIES:
